Hofseth BioCare ASA reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported sales was NOK 33.61 million compared to NOK 15.45 million a year ago. Revenue was NOK 33.61 million compared to NOK 26.08 million a year ago.

Net loss was NOK 38.01 million compared to NOK 37.19 million a year ago. Basic loss per share from continuing operations was NOK 0.1 compared to NOK 0.1 a year ago. Diluted loss per share from continuing operations was NOK 0.1 compared to NOK 0.1 a year ago.